SynAct Pharma AB (SYNACT) - Net Assets
Based on the latest financial reports, SynAct Pharma AB (SYNACT) has net assets worth Skr194.83 Million SEK (≈ $20.97 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Skr253.58 Million ≈ $27.29 Million USD) and total liabilities (Skr58.76 Million ≈ $6.32 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check SynAct Pharma AB liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Skr194.83 Million |
| % of Total Assets | 76.83% |
| Annual Growth Rate | 78.77% |
| 5-Year Change | 1249.68% |
| 10-Year Change | 66827.5% |
| Growth Volatility | 2495.77 |
SynAct Pharma AB - Net Assets Trend (2014–2024)
This chart illustrates how SynAct Pharma AB's net assets have evolved over time, based on quarterly financial data. Also explore SYNACT current and non-current assets for the complete picture of this company's asset base.
Annual Net Assets for SynAct Pharma AB (2014–2024)
The table below shows the annual net assets of SynAct Pharma AB from 2014 to 2024. For live valuation and market cap data, see SynAct Pharma AB market cap and net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | Skr214.17 Million ≈ $23.05 Million |
+21.56% |
| 2023-12-31 | Skr176.19 Million ≈ $18.96 Million |
+39.26% |
| 2022-12-31 | Skr126.52 Million ≈ $13.62 Million |
+506.26% |
| 2021-12-31 | Skr20.87 Million ≈ $2.25 Million |
+31.52% |
| 2020-12-31 | Skr15.87 Million ≈ $1.71 Million |
+17.51% |
| 2019-12-31 | Skr13.50 Million ≈ $1.45 Million |
+30.94% |
| 2018-12-31 | Skr10.31 Million ≈ $1.11 Million |
-20.13% |
| 2017-12-31 | Skr12.91 Million ≈ $1.39 Million |
-52.32% |
| 2016-12-31 | Skr27.08 Million ≈ $2.91 Million |
+8361.75% |
| 2015-12-31 | Skr320.00K ≈ $34.44K |
-50.16% |
| 2014-12-31 | Skr642.00K ≈ $69.09K |
-- |
Equity Component Analysis
This analysis shows how different components contribute to SynAct Pharma AB's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 56843600000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | Skr5.81 Million | 2.71% |
| Other Comprehensive Income | Skr18.56 Million | 8.66% |
| Other Components | Skr762.80 Million | 356.17% |
| Total Equity | Skr214.17 Million | 100.00% |
SynAct Pharma AB Competitors by Market Cap
The table below lists competitors of SynAct Pharma AB ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Mobiletron Electronics Co Ltd
TW:1533
|
$100.91 Million |
|
Shanghai Huili Building Materials Co Ltd
SHG:900939
|
$100.91 Million |
|
Kestrel Group, Ltd.
NYSE:KG
|
$100.95 Million |
|
Vascon Engineers Limited
NSE:VASCONEQ
|
$100.97 Million |
|
Vranken-Pommery Monopole Société Anonyme
PA:VRAP
|
$100.87 Million |
|
CLERHP Estructuras S.A
MC:CLR
|
$100.82 Million |
|
Caravel Minerals Ltd
AU:CVV
|
$100.82 Million |
|
MEI Pharma Inc
NASDAQ:MEIP
|
$100.81 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in SynAct Pharma AB's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 176,186,000 to 214,168,000, a change of 37,982,000 (21.6%).
- Net loss of 82,401,000 reduced equity.
- New share issuances of 94,141,000 increased equity.
- Other comprehensive income increased equity by 2,789,000.
- Other factors increased equity by 23,453,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Skr-82.40 Million | -38.47% |
| Share Issuances | Skr94.14 Million | +43.96% |
| Other Comprehensive Income | Skr2.79 Million | +1.3% |
| Other Changes | Skr23.45 Million | +10.95% |
| Total Change | Skr- | 21.56% |
Book Value vs Market Value Analysis
This analysis compares SynAct Pharma AB's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.25x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2014-12-31 | Skr-0.55 | Skr17.58 | x |
| 2015-12-31 | Skr-0.66 | Skr17.58 | x |
| 2016-12-31 | Skr2.28 | Skr17.58 | x |
| 2017-12-31 | Skr1.04 | Skr17.58 | x |
| 2018-12-31 | Skr0.75 | Skr17.58 | x |
| 2019-12-31 | Skr0.91 | Skr17.58 | x |
| 2020-12-31 | Skr0.73 | Skr17.58 | x |
| 2021-12-31 | Skr0.80 | Skr17.58 | x |
| 2022-12-31 | Skr4.59 | Skr17.58 | x |
| 2023-12-31 | Skr5.42 | Skr17.58 | x |
| 2024-12-31 | Skr5.42 | Skr17.58 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently SynAct Pharma AB utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -38.47%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.26x
- Recent ROE (-38.47%) is above the historical average (-119.99%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2014 | 0.00% | 0.00% | 0.00x | 0.00x | Skr-541.10K |
| 2015 | 0.00% | 0.00% | 0.00x | 0.00x | Skr-502.70K |
| 2016 | -57.08% | 0.00% | 0.00x | 1.13x | Skr-18.16 Million |
| 2017 | -119.23% | 0.00% | 0.00x | 1.18x | Skr-16.69 Million |
| 2018 | -227.35% | 0.00% | 0.00x | 1.36x | Skr-24.48 Million |
| 2019 | -177.42% | 0.00% | 0.00x | 1.76x | Skr-25.31 Million |
| 2020 | -167.32% | 0.00% | 0.00x | 1.36x | Skr-28.14 Million |
| 2021 | -332.09% | 0.00% | 0.00x | 1.84x | Skr-71.39 Million |
| 2022 | -78.41% | 0.00% | 0.00x | 1.13x | Skr-111.86 Million |
| 2023 | -122.49% | 0.00% | 0.00x | 1.29x | Skr-233.43 Million |
| 2024 | -38.47% | 0.00% | 0.00x | 1.26x | Skr-103.82 Million |
Industry Comparison
This section compares SynAct Pharma AB's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $165,054,194
- Average return on equity (ROE) among peers: -81.86%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| SynAct Pharma AB (SYNACT) | Skr194.83 Million | 0.00% | 0.30x | $100.89 Million |
| 2cureX AB (2CUREX) | $74.34 Million | -25.47% | 0.06x | $4.90 Million |
| Ascelia Pharma AB (publ) (ACE) | $74.33 Million | -147.03% | 0.17x | $40.96 Million |
| AcouSort AB (ACOU) | $15.58 Million | -57.51% | 0.12x | $8.97 Million |
| Active Biotech AB (ACTI) | $188.64 Million | -118.73% | 1.64x | $17.19 Million |
| Alzinova AB (ALZ) | $20.63 Million | -16.51% | 0.08x | $4.97 Million |
| AlzeCure Pharma (ALZCUR) | $182.01 Million | -28.02% | 0.03x | $18.18 Million |
| Annexin Pharmaceuticals AB (ANNX) | $18.81 Million | -234.16% | 0.42x | $11.24 Million |
| Alligator Bioscience AB (ATORX) | $68.52 Million | -112.06% | 0.43x | $14.33 Million |
| BioInvent International AB (BINV) | $219.00 Million | -63.86% | 0.22x | $155.44 Million |
| BioArctic AB (publ) (BIOA-B) | $788.68 Million | -15.19% | 0.14x | $2.59 Billion |
About SynAct Pharma AB
SynAct Pharma AB, a clinical stage biotechnology company, researches and develops medicines for the treatment of inflammatory diseases in Sweden. The company develops AP1189, a drug candidate in Phase 2 clinical trial for the treatment of rheumatoid arthritis, idiopathic membranous nephropathy, and virus-induced respiratory insufficiency. It is also developing TXP-11, an advanced peptide agonist … Read more